This guidance clarifies the requirements for product name placement, size, prominence, and frequency in promotional labeling and advertisements for prescription drugs. The disclosure of the product name in promotional labeling and advertisements is important for proper identification and to ensure safe and effective use. This guidance also articulates the circumstances under which FDA intends to refrain from taking enforcement action regarding these requirements. We believe that following this guidance will allow for appropriate advertising and promotion without presenting any public health risk to patients.
News & Trends
Procurar
Recentes
- MDCG Position Paper : Notice to manufacturers and notified bodies to ensure timely compliance with MDR and IVDR requirements
- EFPIA White Paper on Climate Change
- Falsification of medical devices – Results of European survey
- CONTROLO DE ALTERAÇÕES: “Evento super interessante , onde o conhecimento teórico e prático são postos a disposição dos participantes”
- Q&A on the protection of Commercially Confidential Information and Personal Data while using CTIS
- Qualificação de Fornecedores : ” Uma exclelente formação com conhecimentos actualizados e muito interessante . “
- IRIS guide for applicants (How to create and submit IRIS applications, for industry and individual applicants)
- Personal health data: better portability and safe sharing